| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
|
Lancet Oncol
|
2009
|
12.41
|
|
2
|
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
|
Nat Med
|
2013
|
8.89
|
|
3
|
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
|
J Clin Oncol
|
2009
|
6.54
|
|
4
|
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.
|
J Clin Oncol
|
2011
|
5.14
|
|
5
|
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
|
N Engl J Med
|
2015
|
5.08
|
|
6
|
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
|
Blood
|
2009
|
4.74
|
|
7
|
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
|
Blood
|
2003
|
3.61
|
|
8
|
Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.
|
J Clin Oncol
|
2005
|
3.47
|
|
9
|
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
|
Blood
|
2013
|
3.23
|
|
10
|
Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'.
|
Br J Haematol
|
2004
|
2.90
|
|
11
|
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
|
Blood
|
2006
|
2.83
|
|
12
|
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
|
Blood
|
2012
|
2.21
|
|
13
|
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions.
|
Haematologica
|
2007
|
2.05
|
|
14
|
ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases.
|
Blood
|
2003
|
2.05
|
|
15
|
How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?
|
Leuk Lymphoma
|
2014
|
1.99
|
|
16
|
Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
|
Haematologica
|
2005
|
1.92
|
|
17
|
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
|
J Clin Oncol
|
2007
|
1.76
|
|
18
|
Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias.
|
Haematologica
|
2009
|
1.73
|
|
19
|
Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia.
|
Emerg Infect Dis
|
2010
|
1.70
|
|
20
|
A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
|
Blood
|
2011
|
1.69
|
|
21
|
High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis.
|
Blood
|
2003
|
1.66
|
|
22
|
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
|
Blood
|
2008
|
1.64
|
|
23
|
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
|
Am J Med
|
2002
|
1.62
|
|
24
|
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.
|
Blood
|
2004
|
1.57
|
|
25
|
Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma.
|
Clin Lymphoma
|
2003
|
1.52
|
|
26
|
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.
|
Cancer
|
2011
|
1.51
|
|
27
|
Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.
|
Eur J Haematol
|
2010
|
1.50
|
|
28
|
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
|
Clin Cancer Res
|
2007
|
1.50
|
|
29
|
Surveillance for catheter-associated bloodstream infection in hematology units: quantifying the characteristics of a practical case definition.
|
Infect Control Hosp Epidemiol
|
2008
|
1.47
|
|
30
|
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.
|
Leuk Lymphoma
|
2014
|
1.47
|
|
31
|
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
|
Blood
|
2006
|
1.47
|
|
32
|
Fludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenström macroglobulinemia.
|
Leuk Lymphoma
|
2010
|
1.41
|
|
33
|
Chemotherapy versus autologous stem-cell transplantation for the treatment of transformed follicular lymphoma in the rituximab era.
|
J Clin Oncol
|
2013
|
1.39
|
|
34
|
5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen.
|
J Clin Oncol
|
2009
|
1.24
|
|
35
|
Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk.
|
Eur J Haematol
|
2007
|
1.19
|
|
36
|
Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma.
|
Clin Cancer Res
|
2006
|
1.19
|
|
37
|
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial.
|
Haematologica
|
2013
|
1.18
|
|
38
|
Treatment-related myelodysplasia following fludarabine combination chemotherapy.
|
Haematologica
|
2006
|
1.17
|
|
39
|
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
|
Blood
|
2013
|
1.15
|
|
40
|
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
|
J Clin Oncol
|
2006
|
1.14
|
|
41
|
Impact of 18F-fluorodeoxyglucose positron emission tomography before and after definitive radiation therapy in patients with apparently solitary plasmacytoma.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.14
|
|
42
|
Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.
|
Br J Haematol
|
2010
|
1.12
|
|
43
|
Overview of early response assessment in lymphoma with FDG-PET.
|
Cancer Imaging
|
2007
|
1.12
|
|
44
|
Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma.
|
Blood
|
2007
|
1.12
|
|
45
|
Pulmonary alveolar proteinosis.
|
Clin Chest Med
|
2004
|
1.11
|
|
46
|
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*.
|
Br J Haematol
|
2006
|
1.09
|
|
47
|
The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma.
|
Br J Haematol
|
2008
|
1.09
|
|
48
|
Prognostic impact of monocyte count at presentation in mantle cell lymphoma.
|
Br J Haematol
|
2013
|
1.08
|
|
49
|
Infective and thrombotic complications of central venous catheters in patients with hematological malignancy: prospective evaluation of nontunneled devices.
|
Support Care Cancer
|
2008
|
1.07
|
|
50
|
The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement.
|
Eur J Haematol
|
2006
|
1.05
|
|
51
|
Impact of [18f] fluorodeoxyglucose positron emission tomography on staging and management of early-stage follicular non-hodgkin lymphoma.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.04
|
|
52
|
Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope.
|
J Immunol
|
2006
|
1.04
|
|
53
|
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
|
Cancer
|
2006
|
1.03
|
|
54
|
Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
|
Haematologica
|
2005
|
1.02
|
|
55
|
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.
|
Br J Haematol
|
2010
|
1.02
|
|
56
|
Management of the primary cutaneous lymphomas.
|
Australas J Dermatol
|
2003
|
1.00
|
|
57
|
Mice lacking three myeloid colony-stimulating factors (G-CSF, GM-CSF, and M-CSF) still produce macrophages and granulocytes and mount an inflammatory response in a sterile model of peritonitis.
|
J Immunol
|
2007
|
1.00
|
|
58
|
Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
|
Leuk Res
|
2008
|
0.99
|
|
59
|
Primary testicular lymphoma.
|
Blood
|
2013
|
0.97
|
|
60
|
Durable complete molecular remission of chronic myeloid leukemia following dasatinib cessation, despite adverse disease features.
|
Haematologica
|
2011
|
0.96
|
|
61
|
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
|
Blood
|
2003
|
0.93
|
|
62
|
Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy.
|
J Antimicrob Chemother
|
2013
|
0.91
|
|
63
|
Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.
|
Br J Haematol
|
2009
|
0.91
|
|
64
|
Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation.
|
Blood
|
2002
|
0.91
|
|
65
|
Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency.
|
Acta Haematol
|
2013
|
0.91
|
|
66
|
Progress in primary CNS lymphoma.
|
Lancet
|
2009
|
0.90
|
|
67
|
Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
|
J Clin Oncol
|
2006
|
0.90
|
|
68
|
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.
|
Leuk Lymphoma
|
2012
|
0.90
|
|
69
|
Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers.
|
Clin Lymphoma Myeloma
|
2006
|
0.89
|
|
70
|
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.
|
Leuk Lymphoma
|
2012
|
0.89
|
|
71
|
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
|
Clin Cancer Res
|
2005
|
0.89
|
|
72
|
Initial staging of lymphoma with positron emission tomography and computed tomography.
|
Semin Nucl Med
|
2005
|
0.89
|
|
73
|
Enteropathy-associated T-cell lymphoma without a prior diagnosis of coeliac disease: diagnostic dilemmas and management options.
|
Ann Hematol
|
2004
|
0.88
|
|
74
|
Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression.
|
Clin Cancer Res
|
2004
|
0.88
|
|
75
|
Role of 18FDG-positron emission tomography scanning in the management of histiocytosis.
|
Leuk Lymphoma
|
2002
|
0.87
|
|
76
|
Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome.
|
N Engl J Med
|
2004
|
0.87
|
|
77
|
Paraneoplastic large vessel arteritis complicating myelodysplastic syndrome.
|
Leuk Lymphoma
|
2012
|
0.86
|
|
78
|
Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia.
|
J Hematol Oncol
|
2008
|
0.85
|
|
79
|
Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure.
|
Leuk Lymphoma
|
2007
|
0.85
|
|
80
|
Hepatitis-B reactivation and rituximab-containing chemotherapy: an increasingly complex clinical challenge.
|
Leuk Lymphoma
|
2010
|
0.85
|
|
81
|
Bisphosphonate-induced osteonecrosis of the jaw requires early detection and intervention.
|
Med J Aust
|
2005
|
0.84
|
|
82
|
Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan.
|
BMC Pulm Med
|
2014
|
0.84
|
|
83
|
Progressive multifocal leukoencephalopathy complicating Waldenström's macroglobulinaemia.
|
Leuk Lymphoma
|
2003
|
0.83
|
|
84
|
Improved haematopoietic recovery following transplantation with ex vivo-expanded mobilized blood cells.
|
Br J Haematol
|
2004
|
0.82
|
|
85
|
Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study.
|
Leuk Lymphoma
|
2009
|
0.82
|
|
86
|
Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?
|
Curr Oncol Rep
|
2015
|
0.81
|
|
87
|
High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma.
|
Eur J Nucl Med Mol Imaging
|
2013
|
0.81
|
|
88
|
Predicting durable remissions following thalidomide therapy for relapsed myeloma.
|
Leuk Lymphoma
|
2009
|
0.81
|
|
89
|
Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients.
|
Ann Hematol
|
2008
|
0.81
|
|
90
|
Legionella pneumophila mip gene sequencing to investigate a cluster of pneumonia cases.
|
Pathology
|
2003
|
0.81
|
|
91
|
Fertility preservation in female oncology patients.
|
Aust N Z J Obstet Gynaecol
|
2006
|
0.81
|
|
92
|
A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.
|
Aust Health Rev
|
2011
|
0.81
|
|
93
|
Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
|
Leuk Lymphoma
|
2006
|
0.81
|
|
94
|
Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?
|
Leuk Lymphoma
|
2010
|
0.80
|
|
95
|
No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia.
|
Leuk Lymphoma
|
2012
|
0.80
|
|
96
|
The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization.
|
Hematol Oncol
|
2006
|
0.80
|
|
97
|
Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
|
Clin Lymphoma Myeloma
|
2005
|
0.80
|
|
98
|
Role of arsenic trioxide in acute promyelocytic leukemia.
|
Curr Treat Options Oncol
|
2013
|
0.80
|
|
99
|
Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: role of rituximab, high-dose therapy, and allogeneic stem cell transplantation.
|
Leuk Lymphoma
|
2005
|
0.80
|
|
100
|
Treatment of chronic myelomonocytic leukemia with azacitidine.
|
Leuk Lymphoma
|
2012
|
0.80
|
|
101
|
Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia.
|
Leuk Lymphoma
|
2005
|
0.80
|
|
102
|
[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma.
|
Clin Lymphoma Myeloma
|
2008
|
0.79
|
|
103
|
Clinical study of primary cutaneous B-cell lymphoma using both the European Organization for Research and Treatment of Cancer and World Health Organization classifications.
|
Australas J Dermatol
|
2003
|
0.79
|
|
104
|
Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature.
|
Cancer Genet Cytogenet
|
2006
|
0.79
|
|
105
|
Negative selection of chronic lymphocytic leukaemia cells using a bifunctional rosette-based antibody cocktail.
|
BMC Biotechnol
|
2008
|
0.79
|
|
106
|
Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib.
|
Leuk Lymphoma
|
2011
|
0.79
|
|
107
|
Editor in Chief: Response to Eyre et al. "ALK-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease".
|
Eur J Haematol
|
2014
|
0.79
|
|
108
|
Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome.
|
Eur J Haematol
|
2004
|
0.79
|
|
109
|
A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.79
|
|
110
|
A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies.
|
Cancer
|
2004
|
0.79
|
|
111
|
Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP.
|
Leuk Lymphoma
|
2005
|
0.78
|
|
112
|
Fludarabine combinations for patients with advanced marginal zone lymphomas--best treatment option or too toxic?
|
Br J Haematol
|
2009
|
0.78
|
|
113
|
Impairment of peripheral blood stem-cell mobilisation in patients with mantle-cell lymphoma following primary treatment with fludarabine and cyclophosphamide +/- rituximab.
|
Leuk Lymphoma
|
2009
|
0.78
|
|
114
|
Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.
|
Leuk Res
|
2008
|
0.78
|
|
115
|
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis.
|
Br J Haematol
|
2013
|
0.78
|
|
116
|
The role of ancestim (recombinant human stem-cell factor, rhSCF) in hematopoietic stem cell mobilization and hematopoietic reconstitution.
|
Expert Opin Biol Ther
|
2010
|
0.78
|
|
117
|
Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders.
|
Br J Haematol
|
2005
|
0.78
|
|
118
|
A case of chronic lymphocytic leukemia associated with systemic light chain amyloidosis.
|
Leuk Lymphoma
|
2013
|
0.78
|
|
119
|
High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
|
Leuk Lymphoma
|
2013
|
0.77
|
|
120
|
A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
|
Biol Blood Marrow Transplant
|
2005
|
0.77
|
|
121
|
Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients.
|
Eur J Nucl Med Mol Imaging
|
2012
|
0.77
|
|
122
|
Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
|
Eur J Haematol
|
2011
|
0.77
|
|
123
|
Rapid detection of FLT3 exon 20 tyrosine kinase domain mutations in patients with acute myeloid leukemia by high-resolution melting analysis.
|
Leuk Lymphoma
|
2012
|
0.77
|
|
124
|
Alveolar soft-part sarcoma: a cardiac metastasis as a rare site of relapse.
|
Am J Clin Oncol
|
2006
|
0.77
|
|
125
|
The infectious consequences of rituximab addition to fludarabine-containing regimens.
|
Blood
|
2006
|
0.76
|
|
126
|
A phase II study of liposomal daunorubicin, in combination with cyclophosphamide, vincristine and prednisolone, in elderly patients with previously untreated aggressive non-Hodgkin lymphoma.
|
Leuk Lymphoma
|
2008
|
0.76
|
|
127
|
Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.
|
Eur J Haematol
|
2013
|
0.76
|
|
128
|
A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.
|
Br J Haematol
|
2014
|
0.76
|
|
129
|
Optimal approach for high-risk acute promyelocytic leukemia.
|
Curr Opin Hematol
|
2014
|
0.76
|
|
130
|
What is the real risk of central nervous system involvement in mantle cell lymphoma?
|
Leuk Lymphoma
|
2008
|
0.75
|
|
131
|
Follicular lymphoma: is peripheral blood involvement still an adverse prognostic factor in the rituximab era?
|
Leuk Lymphoma
|
2015
|
0.75
|
|
132
|
Is there still a need for specific central nervous system directed prophylaxis for diffuse large B-cell lymphoma in the rituximab era?
|
Leuk Lymphoma
|
2013
|
0.75
|
|
133
|
Osteolytic bone lesions in non-transformed chronic lymphocytic leukemia are not as rare as suggested.
|
Leuk Lymphoma
|
2012
|
0.75
|
|
134
|
What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma?
|
Leuk Lymphoma
|
2008
|
0.75
|
|
135
|
Defining the cost of cure: infertility among female survivors of lymphoma.
|
Leuk Lymphoma
|
2006
|
0.75
|
|
136
|
Hematology: Follicular lymphoma: maintenance therapy is (often) indicated.
|
Nat Rev Clin Oncol
|
2009
|
0.75
|
|
137
|
Strategies to optimize collection of hematopoietic stem cells in patients with mantle cell lymphoma receiving hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate (Hyper-CVAD) chemotherapy.
|
Leuk Lymphoma
|
2011
|
0.75
|
|
138
|
101 years of McCrae's (not Auer's) rods.
|
Br J Haematol
|
2006
|
0.75
|
|
139
|
Under-recognition of platelet dysfunction in myelodysplastic syndromes: are we only seeing the tip of the iceberg?
|
Leuk Lymphoma
|
2012
|
0.75
|
|
140
|
What is responsible for the recent improvements in outlook for patients with follicular lymphoma?
|
Leuk Lymphoma
|
2010
|
0.75
|
|
141
|
New Agents to Treat Chronic Lymphocytic Leukemia.
|
N Engl J Med
|
2016
|
0.75
|
|
142
|
All is not lost--the improving outcome of patients with chronic lymphocytic leukaemia failing frontline therapy with fludarabine, cyclophosphamide and rituximab.
|
Eur J Haematol
|
2013
|
0.75
|
|
143
|
Adding weight to a sinking ship: more reasons not to perform routine surveillance imaging in patients with diffuse large B-cell lymphoma in remission.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
144
|
Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
|
Leuk Lymphoma
|
2010
|
0.75
|
|
145
|
Myeloma and pregnancy: strange bedfellows?
|
Leuk Lymphoma
|
2013
|
0.75
|
|
146
|
Fludarabine, cyclophosphamide, and rituximab chemotherapy followed by rituximab maintenance in follicular lymphoma: high efficacy may come at a cost?
|
Leuk Lymphoma
|
2011
|
0.75
|
|
147
|
Preliminary experience of 18F-fluorodeoxyglucose positron emission tomography in Castleman's disease.
|
Leuk Lymphoma
|
2006
|
0.75
|
|
148
|
Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma.
|
Leuk Lymphoma
|
2013
|
0.75
|
|
149
|
ABVD versus BEACOPP for Hodgkin's lymphoma.
|
N Engl J Med
|
2011
|
0.75
|
|
150
|
The influence of increasing age on the deliverability and toxicity of fludarabine-based combination chemotherapy regimens in patients with indolent lymphoproliferative disorders.
|
Cancer
|
2006
|
0.75
|
|
151
|
A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.
|
Haematologica
|
2008
|
0.75
|
|
152
|
An uncomplicated pregnancy in a woman with smoldering Waldenström macroglobulinemia.
|
Leuk Lymphoma
|
2015
|
0.75
|
|
153
|
Rituximab for the treatment of follicular lymphoma.
|
Future Oncol
|
2013
|
0.75
|
|
154
|
A case of delayed methotrexate clearance following administration of a complementary medication containing chlorophyll.
|
J Oncol Pharm Pract
|
2013
|
0.75
|
|
155
|
Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma.
|
Hematology
|
2014
|
0.75
|
|
156
|
Indolent lymphomas other than follicular and marginal zone lymphomas.
|
Hematol Oncol Clin North Am
|
2008
|
0.75
|
|
157
|
Leukaemic subtype of marginal zone lymphoma: a presentation of three cases and literature review.
|
Leuk Lymphoma
|
2004
|
0.75
|
|
158
|
Bone marrow biopsy for the initial staging of patients with lymphoma: too soon to toss the trephine.
|
Oncology (Williston Park)
|
2013
|
0.75
|
|
159
|
Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis.
|
Leuk Lymphoma
|
2015
|
0.75
|
|
160
|
Early B-cell chronic lymphocytic leukemia presenting as cutaneous lesions with a normal peripheral blood lymphocyte count.
|
J Am Acad Dermatol
|
2005
|
0.75
|
|
161
|
Clonal "devolution" in a case of essential thrombocythemia with transformation from refractory cytopenia with multilineage dysplasia to acute myeloid leukemia.
|
Leuk Lymphoma
|
2006
|
0.75
|
|
162
|
Surveillance of second cancer after previous childhood cancer treatment.
|
Aust Fam Physician
|
2007
|
0.75
|
|
163
|
The Late Effects Clinic in action: for survivors of childhood malignancy.
|
Acta Oncol
|
2007
|
0.75
|
|
164
|
Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase.
|
Leuk Lymphoma
|
2006
|
0.75
|
|
165
|
De novo B-cell prolymphocytic leukemia with central nervous system involvement.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
166
|
Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance.
|
Leuk Lymphoma
|
2013
|
0.75
|
|
167
|
Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.
|
Blood
|
2007
|
0.75
|
|
168
|
A phase II study of liposomal doxorubicin, vincristine and dexamethasone in multiple myeloma.
|
Leuk Lymphoma
|
2005
|
0.75
|
|
169
|
Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
|
Clin Lymphoma
|
2005
|
0.75
|
|
170
|
Intralesional rituximab for the treatment of localised palatal relapse of follicular lymphoma.
|
Leuk Lymphoma
|
2009
|
0.75
|
|
171
|
Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy.
|
Ann Hematol
|
2014
|
0.75
|
|
172
|
Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (HiDAC) based induction chemotherapy.
|
Br J Haematol
|
2012
|
0.75
|
|
173
|
Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
|
Cancer
|
2004
|
0.75
|